Nuvalent (NUVL) Gains from Sales and Divestitures (2022 - 2026)

Nuvalent (NUVL) reported Gains from Sales and Divestitures of $309133.0 for Q1 2026, up 22.28% quarter-over-quarter from $252814.0 in Q4 2025.

Nuvalent (NUVL) Gains from Sales and Divestitures (2022 - 2026) Analysis & Trends

Nuvalent has reported Gains from Sales and Divestitures for 3 years, with the latest figure at $309133.0 in Q1 2026.

For the quarter ending Q1 2026, Gains from Sales and Divestitures changed N/A year-over-year to $309133.0; the trailing twelve-month figure through Mar 2026 stood at $309133.0 (changed N/A YoY), and the FY2025 full-year result was $252814.0, changed N/A from the prior year.
Gains from Sales and Divestitures for Q1 2026 stood at $309133.0, up from $252814.0 in the prior quarter.
The five-year high for Gains from Sales and Divestitures was $309133.0 in Q1 2026, with the low at $21129.0 in Q4 2022.
Historically, Gains from Sales and Divestitures has averaged $206495.2 across 3 years, with a median of $247859.5 in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Nuvalent	9.70 Bn	9.70 Bn	-

Download Data